Application accepted for U.S. FDA Real-Time Oncology Review (RTOR) based on Phase 2b SunRISe-1 study showing highest single-agent complete response rate of 83.5 percent1 RARITAN, NJ – Johnson & Johnson… Read More
The Ministry of Innovation, Science and Economic Development announced funding to establish the National Invention to Innovation (i2I) Network, expanding the award-winning Invention to Innovation program founded at Simon Fraser University (SFU)… Read More
Ontario is the first province in Canada to offer public reimbursement for Pluvicto™, a targeted radioligand therapy for patients with progressive PSMA-positive metastatic castration-resistant prostate cancer The first publicly funded… Read More
Michael King’s strategic networking enables UHN’s critical growth in Toronto’s Discovery District at 522 University Ave. In the heart of Toronto’s Discovery District, life-changing and life-saving research is a part… Read More
Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound® Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC… Read More
